$27.12−2.42 (−8.19%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
Alto Neuroscience (ANRO) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld.
The four lines that matter · FY23–FY25
Revenue ($M)—
0.0
FY23→FY25CAGR —
Net income ($M)▼2.9%
−63.2
FY23→FY25CAGR —
Free cash flow ($M)▼4.6%
−51.8
FY23→FY25CAGR —
Diluted EPS▲12.4%
−2.19
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY23–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6201, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | YoY | CAGR 23→25 |
|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||
Revenue | — | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 72.6 | 45.6 | 47.0 | 30.3 | ▼2.9% | +22.7% |
Selling, general & admin | 28.0 | 20.7 | 21.6 | 7.5 | ▼4.0% | +66.1% |
Total operating expenses | 100.5 | 66.4 | 68.6 | 37.8 | ▼3.3% | +32.5% |
Operating incomefeeds ROC rank | −100.5 | −66.4 | −68.6 | −37.8 | ▲3.3% | — |
Other income, net | 5.4 | 3.1 | 7.2 | 1.5 | — | — |
Pretax income | −95.2 | −63.2 | −61.4 | −36.3 | ▼2.9% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −95.2 | −63.2 | −61.4 | −36.3 | ▼2.9% | — |
| Per share | ||||||
Diluted EPSbuyback-sensitive | −2.45 | −2.19 | −2.50 | −9.73 | ▲12.4% | — |
Diluted shares (mn) | 46.53 | 28.85 | 24.60 | 3.73 | ▲17.3% | +178.1% |
| Margins | ||||||
† TTM = trailing four quarters through 2026-09-30.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-16 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

